By hijacking a process that cells use to keep themselves shipshape, targeted protein degradation has become a hot new area of drug development. In Vivo takes an in-depth look at the field ahead of a wave of data expected this year from early candidates that will give some insight into whether this strategy will truly open a new way to combat disease.

By hijacking a process that cells use to keep themselves shipshape, targeted protein degradation has become a hot new area of drug development. Scrip takes an in-depth look at the field ahead of a wave of data expected this year from early candidates that will give some insight into whether this strategy will truly open a new way to combat disease.

From innovation to legislation, the US audiology market is being shaped by cutting-edge technology from device makers and legislation from the Biden administration to get more hearing aids to those that need them.

Dunad is out-licensing its targeted protein degradation and covalent drug platform to Novartis in a deal that could be worth up to $1.3bn.